Proton Pump Inhibitor Use Linked to Increased Diabetes Risk
Type 2 diabetes risk increased with increasing length of PPI use, particularly use for more than two years.
Diabetes
Major Adverse CV Event Risk Reduced With SGLT2 Inhibitors
Risks for MACE, MI, cardiovascular death, heart failure, all-cause mortality lower versus DPP-4 inhibitors
Riomet ER Recalled Due to NDMA Concerns
The level of NDMA has been found to be above the allowable acceptable daily intake limit established by the FDA.
Metformin May Slow Cognitive Decline in Seniors With T2DM
Cognitive decline slower, dementia risk reduced in seniors with diabetes receiving metformin
Eplerenone May Improve Albumin Excretion in T2D With Acceptable Safety
Research suggests the use of additional treatment options, such as the mineralocorticoid receptor antagonist eplerenone, might prevent or delay overt diabetic nephropathy.
MPR Weekly Dose Podcast Episode 50
We cover AstraZeneca’s decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we wrap up the latest news on drugs in the pipeline.
Trulicity 3mg, 4.5mg Approved for Type 2 Diabetes
The approval was based on data from the randomized, double-blind, parallel-arm phase 3 AWARD-11 trial.
ADA Updates Guideline for Pharmacotherapy of T2DM
Metformin preferred as initial agent; early combined therapy can extend time to treatment failure
Semglee Now Available for Patients With Diabetes
The long-acting human insulin analogue has an identical amino acid sequence to Lantus® (insulin glargine; Sanofi).
Boxed Warning Removed From Canagliflozin Labeling
The FDA concluded “the risk no longer meets the standard for a Boxed Warning.”
